HCPCS Level II code Q5107 designates a 10 mg unit of bevacizumab-awwb (Mvasi), a biosimilar to bevacizumab used primarily in oncology and related indications. This billing code identifies the drug product for billing and inventory purposes and matters nationally because bevacizumab biosimilars affect drug procurement, oncology treatment costs, and payer coverage policies across outpatient infusion settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the code’s clinical context and typical sites of service, as well as what to expect from payer coverage patterns and benchmarks where available. The publication summarizes billing considerations for unit-based biosimilar drug coding, highlights common modifiers used in practice (list provided separately), and outlines the operational implications for hospital outpatient departments and infusion centers.

This overview also describes the practical use of Q5107 on service lines, how it interacts with drug administration workflows, and the types of content included in the full publication (benchmarks, policy updates, and clinical context). Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.